Influenza Prevention in Older Adults
Research activity is centered on influenza virus prevention in adults aged 50 years and older, with particular attention to people ≥65 years and those with stable comorbidities that increase the risk of complications from influenza infection.
- Seasonal influenza vaccination
- Older adult immunization
- Risk reduction in medically vulnerable populations
The sponsor’s work in this area reflects a focus on protecting populations most affected by influenza-related illness and complications.
Adjuvanted and Quadrivalent Vaccine Development
Clinical research includes evaluation of adjuvanted influenza vaccines and quadrivalent vaccine formulations designed to broaden strain coverage and support immune response in older adults.
- Fluad
- Fluad Quadrivalent
- High-dose influenza vaccine
These studies are directed toward influenza vaccine options tailored to age-related immune needs.
Immunogenicity and Serological Response
The sponsor investigates immune responses to influenza vaccination through hemagglutination inhibition measures, geometric mean titers, and seroconversion outcomes across vaccine strains.
- Strain-specific antibody response
- Cell-derived target viruses
- Comparative immunogenicity
This area of work is focused on understanding how different influenza vaccine formulations stimulate protective immune activity.
Vaccine Safety and Tolerability
Trial activity also covers the safety and tolerability of influenza vaccines in large adult populations, including those with underlying health conditions that may affect vaccination outcomes.
- Adult vaccine safety
- Post-vaccination tolerability
- Influenza immunisation in comorbid populations
This therapeutic focus supports the assessment of influenza vaccine use in routine preventive care for older and higher-risk individuals.
